Clinical data | |
---|---|
Trade names | RescueFlow, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration |
intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
Chemical and physical data | |
Molar mass | 70,000 kDa |
Dextran 70 is a type of fluid given by injection into a vein to expand blood volume. Specifically it is used for shock such as that caused by bleeding or burns when blood transfusions are not quickly available. However, it does not carry oxygen.
Common side effects include vomiting, fever, and joint pains. Other side effects include allergic reactions and poor blood clotting. It is not recommended in people with kidney failure, significant heart failure, or a clotting disorder. Use is also not recommended during pregnancy. It works by pulling fluid from the extravascular space into the blood vessels.
Dextran 70 was approved for medical use in 1947. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 4.10 to 5.25 USD per 500 ml. In the United Kingdom this dose costs the NHS about 57.00 pounds. In the United States it costs about 25 to 50 USD per dose. It comes in either sodium chloride solution or glucose solution.